Tamás Lantos

Dr. Tamás Lantos

Department of Medical Physics and Informatics, Albert Szent-Györgyi Medical School, University of Szeged, Szeged, Csongrád, Hungary
orcid
Assistant Professor of Medical Statistics

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2019 in Pancreatology
Verified
Journal Article
Open access
APAndrea Párniczky
Andrea Párniczky
Tamás LantosTamás Lantos
Tamás Lantos
ETEszter Margit Tóth
Eszter Margit Tóth
ZSZsolt Szakács
Zsolt Szakács
SGSzilárd Gódi
Szilárd Gódi
Peter HegyiPeter Hegyi
Peter Hegyi
Unwarranted administration of antibiotics in acute pancreatitis presents a global challenge. The clinical reasoning behind the misuse is poorly understood. Our aim was to investigate current clinical practices and develop recommendations that guide clinicians in prescribing antibiotic treatment in acute pancreatitis. Four methods were used. 1) Systematic data collection was performed to summarize current evidence; 2) a retrospective questionnaire was developed to understand the current global clinical practice; 3) five years of prospectively collected data were analysed to identify the clinical parameters used by medical teams in the decision making process, and finally; 4) the UpToDate Grading of Recommendations, Assessment, Development and Evaluation (GRADE) system was applied to provide evidence based recommendations for healthcare professionals. The systematic literature search revealed no consensus on the start of AB therapy in patients with no bacterial culture test. Retrospective data collection on 9728 patients from 22 countries indicated a wide range (31-82%) of antibiotic use frequency in AP. Analysis of 56 variables from 962 patients showed that clinicians initiate antibiotic therapy based on increased WBC and/or elevated CRP, lipase and amylase levels. The above mentioned four laboratory parameters showed no association with infection in the early phase of acute pancreatitis. Instead, procalcitonin levels proved to be a better biomarker of early infection. Patients with suspected infection because of fever had no benefit from antibiotic therapy. The authors formulated four consensus statements to urge reduction of unjustified antibiotic treatment in acute pancreatitis and to use procalcitonin rather than WBC or CRP as biomarkers to guide decision-making.

23 July 2018 in Planta Medica
Verified
Journal Article
Open access
PDF file
BTBarbara Tóth
Barbara Tóth
PHPéter Hegyi
Péter Hegyi
Tamás LantosTamás Lantos
Tamás Lantos
ZSZsolt Szakács
Zsolt Szakács
BKBeáta Kerémi
Beáta Kerémi
Dezső CsuporDezső Csupor
Dezső Csupor
Herbal products, especially Hypericum perforatum extracts, have been widely used as first-line treatments for mild to moderate depression. Recently, several randomized, controlled clinical trials have been conducted to evaluate the efficacy of another plant, saffron (Crocus sativus), in mild to moderate depression. We have carried out a literature review of currently available published randomized, controlled clinical trials to give an up-to-date evaluation of the efficacy of saffron in mild to moderate depression, compared to placebo or routinely used antidepressants. The meta-analysis is reported according to the preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines using the PICO (patients, intervention, comparison, outcome) format and was conducted using the statistical programs Comprehensive Meta-analysis and RevMan. PubMed, Embase, the Cochrane Central Register of Controlled Trials, and Web of Science databases were searched for relevant studies. Only placebo or active controlled, randomized clinical studies involving patients suffering from mild to moderate depression and using pharmacological doses of saffron per os were included. Hedgesʼ g was used to calculate effect sizes. Risk of bias was assessed using the Cochrane Collaboration tool, and heterogeneity was tested by both performing the Cochranʼs Q test and calculating Higginsʼ I2 indicator. Eleven randomized trials were included in the qualitative analysis, and nine were pooled for statistical analysis. According to the present meta-analysis, saffron has a significant effect on the severity of depression. Available data from randomized, controlled clinical trials support that saffron is significantly more effective than placebo (g = 0.891; 95% CI: 0.369 – 1.412, p = 0.001), and non-inferior to tested antidepressant drugs (g = − 0.246; 95% CI: − 0.495 – 0.004, p = 0.053).

1 November 2018 in Phytomedicine
Verified
Journal Article
Closed access
BTBarbara Tóth
Barbara Tóth
Tamás LantosTamás Lantos
Tamás Lantos
PHPéter Hegyi
Péter Hegyi
RVRéka Viola
Réka Viola
AVAndrea Vasas
Andrea Vasas
Dezső CsuporDezső Csupor
Dezső Csupor

1 December 2019 in Complementary Therapies in Medicine
Verified
Journal Article
Closed access
Dezső CsuporDezső Csupor
Dezső Csupor
Tamás LantosTamás Lantos
Tamás Lantos
PHPéter Hegyi
Péter Hegyi
RBRia Benkő
Ria Benkő
RVRéka Viola
Réka Viola
MMMária Matuz
Mária Matuz

19 November 2018 in Frontiers in Physiology
Verified
Journal Article
Open access
ADAlexandra Demcsák
Alexandra Demcsák
Tamás LantosTamás Lantos
Tamás Lantos
EBEmese Réka Bálint
Emese Réka Bálint
PHPetra Hartmann
Petra Hartmann
Aron VinczeAron Vincze
Aron Vincze
ISImre László Szabó
Imre László Szabó
Background: Clopidogrel and proton pump inhibitors (PPIs) are metabolized by cytochrome P450 enzymes. Contradictory results have been reported on possible complications of simultaneous PPI and clopidogrel use. Our aim was to investigate the clinical relevance of this debate with a systematic review and meta-analysis. Methods: The PubMed, Embase and Cochrane Central Register of Controlled Trials electronic databases were searched for human studies (randomized controlled trials (RCTs) and observational studies) using the PICO format (P: patients on clopidogrel; I: patients treated with PPI; C: patients without PPI treatment; O: cardiovascular risk). We screened eligible studies from 2009 to 2016. After study exclusions, we extracted data from 27 articles for three outcomes: major adverse cardiac event (MACE), myocardial infarction (MI) and cardiovascular (CV) death. The meta-analysis was registered on PROSPERO (CRD42017054316). Results: Data were extracted on 156,823 patients from the 27 trials included (MACE: 23, CV death: 10, MI: 14). The risks of MACE (RR=1.22, 95% CI=1.06–1.396, p=0.004) and MI (RR=1.43, 95% CI=1.24–1.66, p<0.001) were significantly higher in the PPI plus clopidogrel group. However, subgroup analysis demonstrated that this significance disappeared in RCTs (RR=0.99, 95% CI=0.76–1.28, p=0.93) in the MACE outcome group. There was no effect of combined PPI and clopidogrel therapy on CV death outcome (RR=1.21, 95% CI=0.97–1.50, p=0.09). Conclusion: Concomitant use of PPIs and clopidogrel has been proved not to be associated with elevated cardiovascular risks according to RCTs. Based on our results, no restrictions should be applied whenever PPIs and clopidogrel are administered simultaneously.

30 July 2024 in Scientific Reports
Verified
Journal Article
Open access
PDF file
Tamás LantosTamás Lantos
Tamás Lantos
TNTibor András Nyári
Tibor András Nyári
Disasters, including epidemics, have a characteristic course, both in terms of the specific events and the human reactions to them. However, it is difficult to predict whether the COVID-19 pandemic will eventually lead to an increase in suicide rates. We aimed to provide a general pattern of the change in suicide rates in the countries linked to the European Union by direct comparison of the years 2019 and 2020 by gender and age group, grouped according to the predominant religions. Overall, 27 countries were included in the analysis. Incidence rate ratios and their 95% confidence intervals were calculated to characterise annual changes in the incidence of suicide deaths. In almost two-thirds of the countries studied, suicide rates did not increase. The largest increases were observed in Catholic-majority and ‘mixed’ Catholic-Protestant countries, but this was significant only for the oldest age group (over 65 years). This increase was even more marked within some Catholic-majority countries (Hungary, Ireland, and Spain) during the first months of the pandemic. There was no statistically significant increase overall in the suicide death rates in Europe. However, the pattern of suicide rates has changed significantly in some countries, and by age group and religion, respectively.